FDA Acceptance of Supplement for Buprenorphine/Naloxone by Ascent Pharms
The FDA has accepted the supplemental application ANDA219850 for Buprenorphine Hydrochloride and Naloxone Hydrochloride submitted by Ascent Pharms Inc.
Indication
Clinical and regulatory intelligence for Substance Use Disorder with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.